CBIO
Crescent Biopharma, Inc.
Biotechnology
Market Cap$506M
5Y Perf.-95.1%
Build Your Comparison
Side-by-side financial analysisCBIO
RCUS
Try popular comparisons:
Stock Comparison
CBIO vs RCUS
Revenue, margins, valuation, and 5-year total return — side by side.
RCUS
Arcus Biosciences, Inc.
Biotechnology
Market Cap$2.35B
5Y Perf.-5.8%
CBIO vs RCUS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot |  CBIO |  RCUS |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $506M | $2.35B |
| Revenue (TTM) | $12M | $236M |
| Net Income (TTM) | $-162M | $-369M |
| Gross Margin | 100.0% | 90.7% |
| Operating Margin | -13.7% | -168.6% |
| Total Debt | $2M | $99M |
| Cash & Equiv. | $213M | $222M |
CBIO vs RCUS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
CBIO
RCUS
| Stock | Jun 20 | Jun 26 | Return |
|---|---|---|---|
| Crescent Biopharma,… (CBIO) | 100 | 4.9 | -95.1% |
| Arcus Biosciences, … (RCUS) | 100 | 94.2 | -5.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: CBIO vs RCUS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RCUS leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Crescent Biopharma, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
🥇RCUS emerged as the overall leader. Track its performance:
CBIO
Crescent Biopharma, Inc.
The Income Pick
CBIO is the clearest fit if your priority is income & stability and sleep-well-at-night.
- beta 0.82
- Lower volatility, beta 0.82, Low D/E 0.8%, current ratio 6.56x
- Beta 0.82, current ratio 6.56x
Best for: income & stability and sleep-well-at-night
RCUS
Arcus Biosciences, Inc.
The Growth Play
RCUS carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -4.3%, EPS growth -4.8%, 3Y rev CAGR 30.2%
- 37.1% 10Y total return vs CBIO's -97.7%
- -156.4% margin vs CBIO's -13.6%
Best for: growth exposure and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth |  CBIO | 365.3% revenue growth vs RCUS's -4.3% |
| Quality / Margins |  RCUS | -156.4% margin vs CBIO's -13.6% |
| Stability / Safety | CBIO | Beta 0.82 vs RCUS's 1.98, lower leverage |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | RCUS | +156.6% vs CBIO's +10.5% |
| Efficiency (ROA) | RCUS | -35.3% ROA vs CBIO's -88.2% |
CBIO vs RCUS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
FY 2025
CBIO vs RCUS — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRCUSLAGGINGCBIO
CBIOCrescent Biopharma, I…
0leads
RCUSArcus Biosciences, In…
3leads
6 Total Categories
CATEGORYLEADERvs CBIOMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
RCUS4/5
Valuation MetricsMultiples, price ratios, and targets
RCUS2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
Tied
—
Total Returns1Y, 3Y, 5Y total returns with dividends
RCUS5/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
RCUS leads this category, winning 4 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
RCUS is the larger business by revenue, generating $236M annually — 19.9x CBIO's $12M. Profitability is closely matched — net margins range from -156.4% (RCUS) to -13.6% (CBIO).
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… |
|---|---|---|
| RevenueTrailing 12 months | $12M | $236M |
| EBITDAEarnings before interest/tax | -$163M | -$391M |
| Net IncomeAfter-tax profit | -$162M | -$369M |
| Free Cash FlowCash after capex | -$27M | -$489M |
| Gross MarginGross profit ÷ Revenue | +100.0% | +90.7% |
| Operating MarginEBIT ÷ Revenue | -13.7% | -168.6% |
| Net MarginNet income ÷ Revenue | -13.6% | -156.4% |
| FCF MarginFCF ÷ Revenue | -2.3% | -2.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -39.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +10.3% | +10.5% |
RCUS leads this category, winning 4 of 5 comparable metrics.
Valuation Metrics
RCUS leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… |
|---|---|---|
| Market CapShares × price | $506M | $2.3B |
| Enterprise ValueMkt cap + debt − cash | $294M | $2.2B |
| Trailing P/EPrice ÷ TTM EPS | -1.43x | -7.08x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 46.63x | 9.50x |
| Price / BookPrice ÷ Book value/share | 0.94x | 3.97x |
| Price / FCFMarket cap ÷ FCF | — | — |
RCUS leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
Evenly matched — CBIO and RCUS each lead in 4 of 8 comparable metrics.
Profitability & Efficiency
RCUS delivers a -69.0% return on equity — every $100 of shareholder capital generates $-69 in annual profit, vs $-101 for CBIO. CBIO carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to RCUS's 0.16x. On the Piotroski fundamental quality scale (0–9), CBIO scores 7/9 vs RCUS's 0/9, reflecting strong financial health.
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… |
|---|---|---|
| ROE (TTM)Return on equity | -100.9% | -69.0% |
| ROA (TTM)Return on assets | -88.2% | -35.3% |
| ROICReturn on invested capital | — | -64.1% |
| ROCEReturn on capital employed | -132.6% | -42.1% |
| Piotroski ScoreFundamental quality 0–9 | 7 | 0 |
| Debt / EquityFinancial leverage | 0.01x | 0.16x |
| Net DebtTotal debt minus cash | -$212M | -$123M |
| Cash & Equiv.Liquid assets | $213M | $222M |
| Total DebtShort + long-term debt | $2M | $99M |
| Interest CoverageEBIT ÷ Interest expense | -148.19x | -13.38x |
Evenly matched — CBIO and RCUS each lead in 4 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
RCUS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RCUS five years ago would be worth $9,361 today (with dividends reinvested), compared to $667 for CBIO. Over the past 12 months, RCUS leads with a +156.6% total return vs CBIO's +10.5%. The 3-year compound annual growth rate (CAGR) favors RCUS at 5.0% vs CBIO's -53.6% — a key indicator of consistent wealth creation.
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… |
|---|---|---|
| YTD ReturnYear-to-date | +65.5% | +0.0% |
| 1-Year ReturnPast 12 months | +10.5% | +156.6% |
| 3-Year ReturnCumulative with dividends | -90.0% | +15.9% |
| 5-Year ReturnCumulative with dividends | -93.3% | -6.4% |
| 10-Year ReturnCumulative with dividends | -97.7% | +37.1% |
| CAGR (3Y)Annualised 3-year return | -53.6% | +5.0% |
RCUS leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
Evenly matched — CBIO and RCUS each lead in 1 of 2 comparable metrics.
Risk & Volatility
CBIO is the less volatile stock with a 0.82 beta — it tends to amplify market swings less than RCUS's 1.98 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RCUS currently trades 81.1% from its 52-week high vs CBIO's 66.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.82x | 1.98x |
| 52-Week HighHighest price in past year | $27.41 | $28.72 |
| 52-Week LowLowest price in past year | $8.72 | $7.91 |
| % of 52W HighCurrent price vs 52-week peak | +66.9% | +81.1% |
| RSI (14)Momentum oscillator 0–100 | 43.6 | 39.3 |
| Avg Volume (50D)Average daily shares traded | 270K | 1.1M |
Evenly matched — CBIO and RCUS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates CBIO as "Buy" and RCUS as "Buy". Consensus price targets imply 79.9% upside for CBIO (target: $33) vs 33.8% for RCUS (target: $31).
| Metric | CBIOCrescent Biopharm… | RCUSArcus Biosciences… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $33.00 | $31.17 |
| # AnalystsCovering analysts | 13 | 18 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
RCUS leads in 3 of 6 categories — strongest in Income & Cash Flow and Valuation Metrics. 2 categories are tied.
Best OverallArcus Biosciences, Inc. (RCUS)Leads 3 of 6 categories
Loading custom metrics...
CBIO vs RCUS: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is CBIO or RCUS a better buy right now?
Analysts rate Crescent Biopharma, Inc.
(CBIO) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — CBIO or RCUS?
Over the past 5 years, Arcus Biosciences, Inc.
(RCUS) delivered a total return of -6. 4%, compared to -93. 3% for Crescent Biopharma, Inc. (CBIO). Over 10 years, the gap is even starker: RCUS returned +37. 1% versus CBIO's -97. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — CBIO or RCUS?
By beta (market sensitivity over 5 years), Crescent Biopharma, Inc.
(CBIO) is the lower-risk stock at 0. 82β versus Arcus Biosciences, Inc. 's 1. 98β — meaning RCUS is approximately 142% more volatile than CBIO relative to the S&P 500. On balance sheet safety, Crescent Biopharma, Inc. (CBIO) carries a lower debt/equity ratio of 1% versus 16% for Arcus Biosciences, Inc. — giving it more financial flexibility in a downturn.
04Which is growing faster — CBIO or RCUS?
On earnings-per-share growth, the picture is similar: Arcus Biosciences, Inc.
grew EPS -4. 8% year-over-year, compared to -815. 0% for Crescent Biopharma, Inc.. Over a 3-year CAGR, CBIO leads at 424. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — CBIO or RCUS?
Arcus Biosciences, Inc.
(RCUS) is the more profitable company, earning -142. 9% net margin versus -1419. 6% for Crescent Biopharma, Inc. — meaning it keeps -142. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RCUS leads at -156. 3% versus -1407. 5% for CBIO. At the gross margin level — before operating expenses — CBIO leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — CBIO or RCUS?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is CBIO or RCUS better for a retirement portfolio?
For long-horizon retirement investors, Crescent Biopharma, Inc.
(CBIO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 82)). Arcus Biosciences, Inc. (RCUS) carries a higher beta of 1. 98 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CBIO: -97. 7%, RCUS: +37. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between CBIO and RCUS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.